EUCTR2006-006143-31-SE进行中（未招募）不适用
A Phase 3, Open Label Study of Safety and Efficacy of AA4500 in the Treatment of Subjects With Dupuytren's Contracture - Open Label Study of AA4500 in Subjects with Dupuytren's Contracture
Auxilium UK Limited0 个研究点目标入组 240 人开始时间: 2007年9月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following criteria to enter the study:
- •1.Subject is at least 18 years of age.
- •2.Subjects must have a diagnosis of Dupuytren’s contracture with a fixed-flexion (ie, = 20º but = 80º for PIP joint; = 20º but = 100º for MP joint) deformity of at least one finger, other than the thumb, that is caused by a palpable cord.
- •3.Subject must have a positive table top test” defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.
- •4.Subject is naïve to AA4500 treatment or has received one or two injections of AA4500 for the treatment of Dupuytren’s contracture in Auxilium studies AUX CC 851, AUX-CC-853, or AUX-CC-855.
- •5.Subject is judged to be in good health, based upon the results of a medical history, physical examination, and safety laboratory profile.
- •6.Subject voluntarily signs and dates an informed consent agreement approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC).
- •7.Female subjects of child bearing potential must use an acceptable method of birth control or be surgically sterilized or be a post menopausal female (ie, no menses for at least 1 year). A pregnancy test will be performed prior to enrollment in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects will be excluded from study participation for the following reasons:
- •1.Female subjects who are nursing or pregnant, or plan to become pregnant during the treatment phase.
- •2.Subject has a chronic muscular, neurological, or neuromuscular disorder that affects the hands.
- •3.Subject has received an investigational drug within 30 days prior to the first dose of study drug.
- •4.Subject has received treatment for Dupuytren’s contracture within 90 days of enrollment on the joint selected for the initial injection of AA4500. Treatment for Dupuytren’s contracture include surgery (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon.
- •5.Subject has a known allergy to collagenase or any other excipient of AA4500.
- •6.Subject has received doxycycline or doxycycline derivative during the 14 days prior to the first dose of study drug.
- •7.Subject has received any collagenase treatments within 30 days.
- •8.Subject is receiving anticoagulant medication or has received anticoagulant medication (except for aspirin = 150 mg daily) within 7 days before the first injection.
- •9.Subject has a known recent history of stroke, bleeding, a disease process that affects the hands, or other medical condition which in the investigator’s opinion would make the subject unsuitable for enrollment in the study.
研究者
相似试验
进行中（未招募）
不适用
Safety and Efficacy study of BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in untreated Hepatitis C Patients Coinfected with HIV VirusChronic Hepatitis C / HIV-1 co-infectionMedDRA version: 14.1Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-003067-30-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO500
进行中（未招募）
1 期
Safety and Efficacy study of BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in untreated Hepatitis C Patients Coinfected with HIV VirusChronic Hepatitis C / HIV-1 co-infectionMedDRA version: 20.1 Level: PT Classification code 10008912 Term: Chronic hepatitis C System Organ Class: 10021881 - Infections and infestationsEUCTR2011-003067-30-GBBristol-Myers Squibb International Corporation549
进行中（未招募）
不适用
Safety and Efficacy study of BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in untreated Hepatitis C Patients Coinfected with HIV VirusChronic Hepatitis C / HIV-1 co-infectionMedDRA version: 14.0Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-003067-30-ESBristol-Myers Squibb International Corporation500
进行中（未招募）
不适用
Safety and Efficacy study of BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in untreated Hepatitis C Patients Coinfected with HIV VirusChronic Hepatitis C / HIV-1 co-infectionMedDRA version: 16.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-003067-30-DEBristol-Myers Squibb International Corporation500
进行中（未招募）
不适用
Safety and Efficacy study of BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in untreated Hepatitis C Patients Coinfected with HIV VirusChronic Hepatitis C / HIV-1 co-infectionMedDRA version: 16.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-003067-30-BEBristol-Myers Squibb International Corporation500